RIGL

Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. It is focused on products that address signaling pathways that are critical to disease mechanisms. Its first product is TAVALISSE (fostamatinib disodium hexahydrate) tablets, the approved oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Its second product is REZLIDHIA (olutasidenib) capsules for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. Its GAVRETO (pralsetinib) product is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions.

Wall Street analysts forecast RIGL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RIGL is 45.67 USD with a low forecast of 38.00 USD and a high forecast of 57.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Rigel Pharmaceuticals Inc revenue for the last quarter amounts to 69.46M USD, increased 25.59 % YoY.

Rigel Pharmaceuticals Inc. EPS for the last quarter amounts to 1.46 USD, increased 108.57 % YoY.

Rigel Pharmaceuticals Inc (RIGL) has 162 emplpoyees as of December 15 2025.

Today RIGL has the market capitalization of 740.21M USD.